Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study
<p>Abstract</p> <p>Background</p> <p>The breast is a rare extranodal site of non-Hodgkin lymphoma, and primary breast lymphoma (PBL) has been arbitrarily defined as disease localized to one or both breasts with or without regional lymph nodes involvement. The aim of thi...
Main Authors: | , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-06-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/321 |
id |
doaj-f22fac37d94a44cf99b5f8b406559773 |
---|---|
record_format |
Article |
spelling |
doaj-f22fac37d94a44cf99b5f8b4065597732020-11-24T21:41:37ZengBMCBMC Cancer1471-24072010-06-0110132110.1186/1471-2407-10-321Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) studyLee Je-JungShim HyeokWon Jong-HoLee JaeKim Jeong-AEom HyeonOh SungChoi ChulKim JinChae YeeKim WonKim SeokChoi YoonKang HyeYhim Ho-YoungSung HwaKim HyoLee DaeSuh CheolwonKwak Jae-Yong<p>Abstract</p> <p>Background</p> <p>The breast is a rare extranodal site of non-Hodgkin lymphoma, and primary breast lymphoma (PBL) has been arbitrarily defined as disease localized to one or both breasts with or without regional lymph nodes involvement. The aim of this study was to evaluate the clinical outcomes in patients with diffuse large B cell lymphoma (DLBCL) and breast involvement, and to find the criteria of PBL reflecting the outcome and prognosis.</p> <p>Methods</p> <p>We retrospectively analyzed data from 68 patients, newly diagnosed with DLBCL and breast involvement at 16 Korean institutions between January 1994 and June 2009.</p> <p>Results</p> <p>Median age at diagnosis was 48 years (range, 20-83 years). Forty-three (63.2%) patients were PBL according to previous arbitrary criteria, sixteen (23.5%) patients were high-intermediate to high risk of international prognostic index. The patients with one extranodal disease in the breast (OED) with or without nodal disease were 49 (72.1%), and those with multiple extranodal disease (MED) were 19 (27.9%). During median follow-up of 41.5 months (range, 2.4-186.0 months), estimated 5-year progression-free survival (PFS) was 53.7 ± 7.6%, and overall survival (OS) was 60.3 ± 7.2%. The 5-year PFS and OS was significantly higher for patients with the OED group than those with the MED group (5-year PFS, 64.9 ± 8.9% vs. 27.5 ± 11.4%, p = 0.001; 5-year OS, 74.3 ± 7.6% vs. 24.5 ± 13.0%, p < 0.001). In multivariate analysis, MED (hazard ratio [HR], 3.61; 95% confidence interval [CI], 1.07-12.2) and fewer than four cycles of systemic chemotherapy with or without local treatments (HR, 4.47; 95% CI, 1.54-12.96) were independent prognostic factors for worse OS. Twenty-five (36.8%) patients experienced progression, and the cumulative incidence of progression in multiple extranodal sites or other than breasts and central nervous system was significantly different between the OED group and the MED group (5-year cumulative incidence, 9.7 ± 5.4% vs. 49.0 ± 15.1%, p = 0.001).</p> <p>Conclusions</p> <p>Our results show that the patients included in OED group, reflecting different treatment outcome, prognosis and pattern of progression, should be considered as PBL in the future trial. Further studies are warranted to validate our suggested criteria.</p> http://www.biomedcentral.com/1471-2407/10/321 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lee Je-Jung Shim Hyeok Won Jong-Ho Lee Jae Kim Jeong-A Eom Hyeon Oh Sung Choi Chul Kim Jin Chae Yee Kim Won Kim Seok Choi Yoon Kang Hye Yhim Ho-Young Sung Hwa Kim Hyo Lee Dae Suh Cheolwon Kwak Jae-Yong |
spellingShingle |
Lee Je-Jung Shim Hyeok Won Jong-Ho Lee Jae Kim Jeong-A Eom Hyeon Oh Sung Choi Chul Kim Jin Chae Yee Kim Won Kim Seok Choi Yoon Kang Hye Yhim Ho-Young Sung Hwa Kim Hyo Lee Dae Suh Cheolwon Kwak Jae-Yong Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study BMC Cancer |
author_facet |
Lee Je-Jung Shim Hyeok Won Jong-Ho Lee Jae Kim Jeong-A Eom Hyeon Oh Sung Choi Chul Kim Jin Chae Yee Kim Won Kim Seok Choi Yoon Kang Hye Yhim Ho-Young Sung Hwa Kim Hyo Lee Dae Suh Cheolwon Kwak Jae-Yong |
author_sort |
Lee Je-Jung |
title |
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study |
title_short |
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study |
title_full |
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study |
title_fullStr |
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study |
title_full_unstemmed |
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study |
title_sort |
clinical outcomes and prognostic factors in patients with breast diffuse large b cell lymphoma; consortium for improving survival of lymphoma (cisl) study |
publisher |
BMC |
series |
BMC Cancer |
issn |
1471-2407 |
publishDate |
2010-06-01 |
description |
<p>Abstract</p> <p>Background</p> <p>The breast is a rare extranodal site of non-Hodgkin lymphoma, and primary breast lymphoma (PBL) has been arbitrarily defined as disease localized to one or both breasts with or without regional lymph nodes involvement. The aim of this study was to evaluate the clinical outcomes in patients with diffuse large B cell lymphoma (DLBCL) and breast involvement, and to find the criteria of PBL reflecting the outcome and prognosis.</p> <p>Methods</p> <p>We retrospectively analyzed data from 68 patients, newly diagnosed with DLBCL and breast involvement at 16 Korean institutions between January 1994 and June 2009.</p> <p>Results</p> <p>Median age at diagnosis was 48 years (range, 20-83 years). Forty-three (63.2%) patients were PBL according to previous arbitrary criteria, sixteen (23.5%) patients were high-intermediate to high risk of international prognostic index. The patients with one extranodal disease in the breast (OED) with or without nodal disease were 49 (72.1%), and those with multiple extranodal disease (MED) were 19 (27.9%). During median follow-up of 41.5 months (range, 2.4-186.0 months), estimated 5-year progression-free survival (PFS) was 53.7 ± 7.6%, and overall survival (OS) was 60.3 ± 7.2%. The 5-year PFS and OS was significantly higher for patients with the OED group than those with the MED group (5-year PFS, 64.9 ± 8.9% vs. 27.5 ± 11.4%, p = 0.001; 5-year OS, 74.3 ± 7.6% vs. 24.5 ± 13.0%, p < 0.001). In multivariate analysis, MED (hazard ratio [HR], 3.61; 95% confidence interval [CI], 1.07-12.2) and fewer than four cycles of systemic chemotherapy with or without local treatments (HR, 4.47; 95% CI, 1.54-12.96) were independent prognostic factors for worse OS. Twenty-five (36.8%) patients experienced progression, and the cumulative incidence of progression in multiple extranodal sites or other than breasts and central nervous system was significantly different between the OED group and the MED group (5-year cumulative incidence, 9.7 ± 5.4% vs. 49.0 ± 15.1%, p = 0.001).</p> <p>Conclusions</p> <p>Our results show that the patients included in OED group, reflecting different treatment outcome, prognosis and pattern of progression, should be considered as PBL in the future trial. Further studies are warranted to validate our suggested criteria.</p> |
url |
http://www.biomedcentral.com/1471-2407/10/321 |
work_keys_str_mv |
AT leejejung clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT shimhyeok clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT wonjongho clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT leejae clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT kimjeonga clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT eomhyeon clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT ohsung clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT choichul clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT kimjin clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT chaeyee clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT kimwon clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT kimseok clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT choiyoon clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT kanghye clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT yhimhoyoung clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT sunghwa clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT kimhyo clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT leedae clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT suhcheolwon clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy AT kwakjaeyong clinicaloutcomesandprognosticfactorsinpatientswithbreastdiffuselargebcelllymphomaconsortiumforimprovingsurvivaloflymphomacislstudy |
_version_ |
1725920987539570688 |